163 related articles for article (PubMed ID: 35414476)
41. Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Paul B; Hamadeh I; Atrash S; Bhutani M; Voorhees P; Usmani SZ
Expert Opin Biol Ther; 2020 Nov; 20(11):1253-1259. PubMed ID: 32750265
[TBL] [Abstract][Full Text] [Related]
42. Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.
King T; Jagger J; Wood J; Woodrow C; Snowden A; Haines S; Crosbie C; Houdyk K
Asia Pac J Oncol Nurs; 2018; 5(3):270-284. PubMed ID: 29963589
[TBL] [Abstract][Full Text] [Related]
43. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
44. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
46. Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Drill E; Qiu A; Shapouri S; To TM; Ravelo A; Schade J; Dawson K; Matasar M
Oncology (Williston Park); 2021 Dec; 35(12):804-811. PubMed ID: 35089000
[TBL] [Abstract][Full Text] [Related]
47. Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010).
An G; Ge Z; Jing H; Liu J; Yang G; Feng R; Xu Z; Qi M; Wang J; Song J; Zhou W; Sun B; Zhu D; Chen X; Cui C; Qiu L
Blood Sci; 2024 Jul; 6(3):e00193. PubMed ID: 38832105
[TBL] [Abstract][Full Text] [Related]
48. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.
Quach H; Parmar G; Mateos MV; Ailawadhi S; Leleu X
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):358-363. PubMed ID: 38519329
[TBL] [Abstract][Full Text] [Related]
49. Monoclonal antibody utilization characteristics in patients with multiple myeloma.
Ailawadhi S; Sher T; Azzouqa AG; Meghji Z; Jain T; Jani P; Ahmed S; Diehl N; Roy V; Shah V; Hodge D; Ailawadhi M; Alegria VR; Paulus A; Chanan-Khan A; Fonseca R
Anticancer Drugs; 2019 Sep; 30(8):859-865. PubMed ID: 31415286
[TBL] [Abstract][Full Text] [Related]
50. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
51. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
[TBL] [Abstract][Full Text] [Related]
52. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Usmani SZ; Mateos MV; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
J Cancer Res Clin Oncol; 2021 Feb; 147(2):619-631. PubMed ID: 32852632
[TBL] [Abstract][Full Text] [Related]
53. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
Luo MM; Zhu PP; Nnane I; Xiong Y; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Weiss BM; Tran N; Qin X; Vermeulen J; Sharma A; Sun YN; Zhou H
J Clin Pharmacol; 2022 May; 62(5):656-669. PubMed ID: 34708423
[TBL] [Abstract][Full Text] [Related]
54. Daratumumab for the treatment of multiple myeloma.
Goldsmith SR; Foley N; Schroeder MA
Drugs Today (Barc); 2021 Oct; 57(10):591-605. PubMed ID: 34713868
[TBL] [Abstract][Full Text] [Related]
55. Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Cohen YC; Oriol A; Wu KL; Lavi N; Vlummens P; Jackson C; Garvin W; Carson R; Crist W; Fu J; Feng H; Xie H; Schecter J; San-Miguel J; Lonial S
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):46-54.e4. PubMed ID: 33485428
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
57. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Bladé J; Luo M; Sun YN; Zhou H; Nnane I; Deraedt W; Qi M; Ukropec J; Clemens PL
Adv Ther; 2020 Apr; 37(4):1464-1478. PubMed ID: 32078124
[TBL] [Abstract][Full Text] [Related]
58. Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.
Cook G; Ashcroft J; Fernandez M; Henshaw S; Khalaf Z; Pratt G; Tailor A; Rabin N
Front Oncol; 2023; 13():1063144. PubMed ID: 36910662
[TBL] [Abstract][Full Text] [Related]
59. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
60. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma.
Al Hadidi S; Miller-Chism CN; Kamble R; Mims M
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e579-e589. PubMed ID: 32409106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
